Cargando…

Is There a Significant Difference in Acute Kidney Injury Incidence Among Patients Treated with Vancomycin Combined with Cefepime or Meropenem?

BACKGROUND: Acute kidney injuries (AKIs) are common among patients receiving concomitant vancomycin (VAN) and piperacillin-tazobactam, especially compared with cefepime (FEP) with vancomycin. It is unknown if there is a significant difference between therapeutic alternatives to piperacillin-tazobact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rutter, W Cliff, Burgess, David S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631476/ http://dx.doi.org/10.1093/ofid/ofx163.803

Ejemplares similares

Incidence of Acute Kidney Injury Among Intensive Care Unit Patients Receiving Vancomycin in Combination with Cefepime or Piperacillin–Tazobactam
por: Rutter, W Cliff, et al.
Publicado: (2017)

Impact of Obesity on Acute Kidney Injury Incidence Among Patients Treated with Piperacillin–Tazobactam and Vancomycin
por: Rutter, W Cliff, et al.
Publicado: (2017)

50. Comparative Incidence of Acute Kidney Injury in Septic Patients Treated with Vancomycin in Combination with Piperacillin/Tazobactam vs. Cefepime
por: Deja, Erin, et al.
Publicado: (2020)

212. Acute Kidney Injury with Piperacillin-tazobactam versus Cefepime in Combination with Vancomycin
por: Nguyen, Phuong Khanh, et al.
Publicado: (2020)

Comparison of Rates of Acute Kidney Injury with Vancomycin/Piperacillin-Tazobactam vs. Vancomycin/Meropenem Combination Therapy
por: Pernia, Sonia, et al.
Publicado: (2017)

2221. Comparison of Vancomycin with Either Piperacillin/Tazobactam or Cefepime for the Incidence of Acute Kidney Injury in a Patient Population with a High Prevalence of Preexisting Kidney Dysfunction
por: Moran, Ryan, et al.
Publicado: (2023)

Progression of kidney injury with the combination of vancomycin and piperacillin-tazobactam or cefepime in sepsis-associated acute kidney injury
por: Whitenack, Kaylee, et al.
Publicado: (2022)

Early Antimicrobial De-escalation Is Associated with Decreased Acute Kidney Injury in Patients Receiving Empiric Combination Therapy
por: Rutter, W Cliff, et al.
Publicado: (2017)

In vitro Activity of Fosfomycin, Alone and Combined with Cefepime and Meropenem, Against Carbapenemase-Producing Gram-Negative Bacteria
por: Wiederhold, Nathan P, et al.
Publicado: (2017)

Acute Kidney Injury Associated with Combination Antimicrobial Therapy in the Medical Information Mart for Intensive Care (MIMIC) III Database
por: Rutter, W Cliff, et al.
Publicado: (2017)

Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study
por: Sipahi, Oguz Resat, et al.
Publicado: (2023)

1411. Tecioplanin (TEI) vs. Vancomycin (VAN) in Combination with Piperacillin-Tazobactam (TZP) or Meropenem (MER) as a Cause of Acute Kidney Injury (AKI)
por: Aslan, Abdullah Tarik, et al.
Publicado: (2018)

1228. Outcomes Associated with Empiric Cefepime or Meropenem for Bloodstream Infections Caused by Ceftriaxone-Resistant, Cefepime-Susceptible Escherichia coli and Klebsiella pneumoniae
por: Frescas, Brian E, et al.
Publicado: (2021)

2795. Cefepime Versus Meropenem for Infections Due to HECCcK-YeS-MAm Organisms with Cefepime MICs of 4-8 mCg/mL (S-DD)
por: Purdy, Andrew Scott, et al.
Publicado: (2023)

2292. Incidence of Acute Kidney Injury Associated with Duration of Vancomycin and Piperacillin/tazobactam Combination Therapy
por: McMullen, Lisanne, et al.
Publicado: (2019)

1244. Evaluation of Intraoperative Topical Vancomycin and the Incidence of Acute Kidney Injury
por: Blackman, Alison L, et al.
Publicado: (2019)

26. in Vitro selection Of enterobacter Cloacae with Cefepime, Meropenem, and Ceftazidime-avibactam Generate Diverse Resistance Mechanism
por: Castanheira, Mariana, et al.
Publicado: (2020)

Comparison of Acute Kidney Injury During Treatment with Vancomycin and either Piperacillin-Tazobactam or Meropenem
por: Cannon, John M., et al.
Publicado: (2017)

A retrospective cohort study assessing acute kidney injury and renal recovery among septic patients empirically treated with vancomycin piperacillin–tazobactam versus vancomycin cefepime
por: Elliott, Brian Pacca, et al.
Publicado: (2021)

In Vivo Efficacy of Humanized Exposures of Cefiderocol Compared with Cefepime (FEP) and Meropenem (MEM) against Gram-negative Bacteria in a Murine Thigh Model
por: Monogue, Marguerite, et al.
Publicado: (2017)

1100. A Prospective Evaluation of Neurotoxicity Among Patients Receiving Dose-Optimized Cefepime or Meropenem With Concomitant Therapeutic Drug Monitoring
por: Smith, Brandon, et al.
Publicado: (2021)

2877. Influence of vancomycin AUC monitoring on acute kidney injury in a large quasi-experimental study of over 3000 patients
por: Gregory, Eric, et al.
Publicado: (2023)

2558. Association of Vancomycin-Induced Acute Kidney Injury with Trough Versus AUC Monitoring in Patients Receiving Extended Durations of Therapy
por: Pitcock, C Tyler, et al.
Publicado: (2023)

400. Comparison of Tolerance and Microbiological Efficacy of Cefepime and Piperacillin/Tazobactam in Combination with Vancomycin as Empirical Antimicrobial Therapy of Prosthetic Joint Infection: A Propensity-Matched Cohort Study
por: Triffault-Fillit, Claire, et al.
Publicado: (2019)

Activity of Imipenem, Meropenem, Cefepime, and Sulbactam in Combination with the β-Lactamase Inhibitor LN-1-255 against Acinetobacter spp.
por: Lasarte-Monterrubio, Cristina, et al.
Publicado: (2021)

Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin
por: SRİSRATTAKARN, Arpasiri, et al.
Publicado: (2021)

610. Incidence of Acute Kidney Injury in Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Vancomycin
por: Hamad, Yasir, et al.
Publicado: (2020)

2244. Clinical Outcomes with Extended Infusion (EI) vs. Intermittent Infusion (II) of Cefepime (FEP), Piperacillin/Tazobactam (TZP), and Meropenem (MEM) in Patients with Gram-Negative (GN) Bacteremia
por: Tran, Kieu-Nhi, et al.
Publicado: (2019)

2436. Use of Piperacillin/Tazobactam vs. Cefepime or Carbapenem for Infections Due to Serratia, Citrobacter, or Enterobacter
por: Go, James, et al.
Publicado: (2018)

2669. Evaluation of Post-Operative Acute Kidney Injury with Piperacillin–Tazobactam Combined with Vancomycin for Lung Transplant Prophylaxis
por: Pettit, Natasha N, et al.
Publicado: (2019)

Impact of Vancomycin Serum Trough Concentrations and Vancomycin AUC/MIC on Vancomycin Response, In-Hospital Outcomes and Acute Kidney Injury in Pediatric Staphylococcus aureus Pneumonia
por: McNeil, Jonathon, et al.
Publicado: (2017)

Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study
por: Kadomura, Shota, et al.
Publicado: (2019)

Impact of Vancomycin-Associated Acute Kidney Injury on Patient Outcomes in MRSA Bacteremia
por: Luther, Megan, et al.
Publicado: (2017)

1382. Acute Kidney Injury with Piperacillin–tazobactam and Vancomycin in the Intensive Care Unit
por: Smith, Tameka, et al.
Publicado: (2018)

220. Acute kidney injury incidence comparison of vancomycin trough-based vs AUC/MIC monitoring at a tertiary care hospital
por: Ruiz Gaviria, Rafael E, et al.
Publicado: (2022)

Vancomycin Intoxication and Cefepime-induced Encephalopathy Treated by Abdominal Drainage of Massive Ascites in Addition to Online Hemodiafiltration
por: Taniguchi, Tomoki, et al.
Publicado: (2021)

1380. Effect of Absolute Body Weight on Clinical Outcomes of Obese Patients Treated with Cefepime
por: Wagner, Jamie L, et al.
Publicado: (2018)

1318. Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment
por: Geibel, Brooke, et al.
Publicado: (2020)

The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin
por: Zasowski, Evan J, et al.
Publicado: (2019)

2551. Assessing Meropenem Concentrations in Children with Septic Shock: Population-Based Pharmacokinetic (PK) Modeling of Meropenem Demonstrates Variability from Acute Kidney (AKI) to Augmented Renal Clearance (ARC)
por: Le, Jennifer, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_59k3ss45kj7jnmtar77ll8mepr